The latest announcement is out from Alkermes ( (ALKS) ).

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1, based ...

Alixorexton is an oral selective orexin 2 receptor agonist expected to reduce excessive daytime sleepiness across hypersomnolence disorders such as narcolepsy.

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...

Investing.com -- Alkermes Plc (NASDAQ:ALKS) stock rose 3.4% in premarket trade Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to the company’s ...

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...

AXS-12's clinical development program in narcolepsy includes three controlled efficacy trials, and a completed long-term safety trial. The drug has already been granted orphan drug designation, a ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with lifestyle ...

As a sleep specialist, I find it incredibly rewarding to treat people with narcolepsy. It can be unnerving to be diagnosed with the disorder. But it’s also a huge relief, because people finally know ...

Aaron Schokman is a member of the Sleep Health Foundation’s Consumer Reference Council. He has also received funding from the American Academy of Sleep Medicine Foundation for narcolepsy related ...